BEIJING and SHANGHAI and BOSTON, December 5, 2021 / PRNewswire / – Jacobio Pharma (1167.HK) received the new investigational drug ( “IND “) the approval of the combination therapy of KRAS inhibitor G12C JAB-21822 and Cetuximab injection from the Center for Drug Evaluation of China (the “CDE “) on Dec 3 2021.
After has received approval, Jacobio will enter phase I / II, open-label, multicenter, escalating dose and clinically expanding trialI am in China. The clinic trial aims to explore the safety, tolerability and preliminary efficacy of the combination therapy of JAB-21822 and Cetuximab in KRAS G12C mutant patients with advanced colorectal cancer.
Jacobio’s preclinical study shows that the combination therapy of JAB-21822 and Cetuximab can improve the anti-tumor activity of JAB-21822 inhibitors in colorectal cancer tumor models, induce tumor regression and delay tumor regrowth after the cessation of using the drug.
JAB-21822 has been approved for five clinical trials in China and United States, including monotherapies and combination therapies with PD-1 antibody or cetuximab to treat KRAS G12C mutant patients with advanced solid tumors, including non-small cell lung cancer and colorectal cancer.
JAB-21822 is Jacobio’s innovative small molecule anticancer drug designed to target the KRAS G12C mutation. JAB-21822 has the best potential among KRAS G12C inhibitors and has been approved for clinical trials in China and United States. In-house, face-to-face preclinical studies have shown this JAB-21822 To a higher pharmacokinetic (PK) profile and favorable tolerance as well as a potential for a higher dosage profile compared with its competitors.
Cetuximab is an IgG1 monoclonal antibody directed against the EGF receptor. Cetuximab injection used in the clinical trial of combination therapy is an approved the treatment of wild-type RAS patients with metastatic colorectal cancer, head and neck cancers and other diseases.
Jacobio is committed to providing more products and solutions for the health of people. Our mission is to deliver compelling innovations to create a pipeline of life-changing drugs. Our vision is to become a world leader recognized for our impact in drug R&D with our partners. The company’s R&D centers are located in Beijing, Shanghai and Massachusetts, with a platform and expertise in the development of allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcription factors.
SOURCE Jacobio Pharma